What Makes It Tick: Exploring the Mechanisms of Post-treatment Lyme Disease Syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review of proposed pathophysiological mechanisms without original human data or systematic synthesis
PubMed 39161484 · doi:10.7759/cureus.64987
What was done
Narrative review synthesizing proposed pathophysiological mechanisms, diagnostic challenges, and future research directions for post-treatment Lyme disease syndrome (PTLDS), defined by the IDSA as fatigue, pain, or cognitive symptoms lasting over six months after antibiotic treatment.
What was found
The authors report that PTLDS symptoms occur in 10%-20% of patients with appropriately treated Lyme disease. Proposed mechanisms include permanent tissue damage and inflammation, immune dysfunction, autoimmune response, co-infection, and persistent infection. The authors propose that ongoing symptoms relate to an autoimmune response to tissue damage and inflammation caused by viable or nonviable spirochetes. As of 2024, no quantifiable laboratory or tissue diagnostics exist, leaving PTLDS as a clinical diagnosis.
Why it matters
The paper contextualizes persistent post-Lyme symptoms alongside conditions like long COVID and chronic fatigue syndrome, emphasizing the need for biomarker discovery and genomic research.
Limits
This is an unsystematic narrative overview without original data or a formal search protocol. The abstract does not report the number of studies reviewed, and objective diagnostic criteria remain unavailable.
Cited by
- supports The scientific consensus among infectious disease specialists is that broad-spectrum antibiotics eradicate Borrelia spirochetes, with no evidence that they survive or hide in biofilms to cause chronic Lyme infection.